MK 966
Categoria
MK 966 Marchi, MK 966 Analoghi
MK 966 Marchi miscela
MK 966 Formula chimica
C17H14O4S
MK 966 RX link
http://www.rxlist.com/cgi/generic/rofecox.htm
MK 966 FDA foglio
MK 966 DMS (foglio di materiale di sicurezza)
MK 966 Sintesi di riferimento
Nessuna informazione disponibile
MK 966 Peso molecolare
314.357 g/mol
MK 966 Temperatura di fusione
No information avaliable
MK 966 H2O Solubilita
Insolubile
MK 966 Stato
Solid
MK 966 LogP
3.019
MK 966 Forme di dosaggio
Compressa (12,5 mg, 25 mg o 50 mg), sospensione orale (12,5 o 25 mg per 5 ml di soluzione)
MK 966 Indicazione
Per il trattamento di osteoartrosi, dolore acuto negli adulti e nei dolori mestruali.
MK 966 Farmacologia
Rofecoxib, un selettivo della cicloossigenasi-2 (COX-2) inibitore, è classificato come un farmaco anti-infiammatori non steroidei (FANS). Il rofecoxib è utilizzato per le sue attività anti-infiammatori, analgesici e antipiretici nella gestione dell'osteoartrosi (OA) e per il trattamento della dismenorrea o dolore acuto. A differenza di celecoxib, rofecoxib manca di una catena di sulfonamide e non richiede per il metabolismo degli enzimi CYP450.
MK 966 Assorbimento
La biodisponibilità orale media di rofecoxib a dosi terapeuticamente raccomandata di 12,5, 25 e 50 mg è circa il 93%.
MK 966 Tossicita
Nessun overdose del rofecoxib sono stati segnalati durante gli studi clinici. La somministrazione di dosi singole di rofecoxib 1000 mg a 6 volontari sani e dosi multiple di 250 mg / die per 14 giorni a 75 volontari sani non ha causato una grave tossicità.
MK 966 Informazioni paziente
PATIENT INFORMATION
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
MK 966 Atto interessato organismi
Gli esseri umani e altri mammiferi
